Biomarker Analysis Beyond Angiogenesis: RAS/RAF Mutation Status, Tumour Sidedness, and Second-Line Ramucirumab Efficacy in Patients With Metastatic Colorectal Carcinoma From RAISE, a Global Phase 3 Study

Annals of Oncology - United Kingdom
doi 10.1093/annonc/mdy461
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Baseline Carcinoembryonic Antigen as a Predictive Factor of Ramucirumab Efficacy in RAISE, a Second-Line Metastatic Colorectal Carcinoma Phase III Trial

European Journal of Cancer
Cancer ResearchOncology
2017English

Impact of Tumour RAS/BRAF Status in a First-Line Study of Panitumumab + FOLFIRI in Patients With Metastatic Colorectal Cancer

British Journal of Cancer
Cancer ResearchOncology
2016English

The Clinical Benefit of Bevacizumab in Metastatic Colorectal Cancer Is Independent of K-Ras Mutation Status: Analysis of a Phase III Study of Bevacizumab With Chemotherapy in Previously Untreated Metastatic Colorectal Cancer

Oncologist
Cancer ResearchMedicineOncology
2009English

Mutation Analysis of Key Genes in RAS/RAF and PI3K/PTEN Pathways in Chinese Patients With Hepatocellular Carcinoma

Oncology Letters
Cancer ResearchOncology
2014English

A Multi-Center Phase II Study and Biomarker Analysis of Combined Cetuximab and Modified FOLFIRI as Second-Line Treatment in Patients With Metastatic Gastric Cancer

BMC Cancer
Cancer ResearchOncologyGenetics
2017English

Metastatic Colorectal Cancer First-Line Treatment With Bevacizumab: The Impact of K-Ras Mutation

OncoTargets and Therapy
OncologyPharmacology
2013English

Deficient Mismatch Repair and RAS Mutation in Colorectal Carcinoma Patients: A Retrospective Study in Eastern China

PeerJ
GeneticsMolecular BiologyBiochemistryBiological SciencesMedicineAgriculturalNeuroscience
2018English

Efficacy, Tolerability, and Biomarker Analyses of Once-Every-2-Weeks Cetuximab Plus First-Line FOLFOX or FOLFIRI in Patients With KRAS or All RAS Wild-Type Metastatic Colorectal Cancer: The Phase 2 APEC Study

Clinical Colorectal Cancer
OncologyGastroenterology
2017English

Impact of Primary Tumour Location on Second- Or Later-Line Treatment Outcomes in Patients With RAS Wild-Type Metastatic Colorectal Cancer and in All Lines of Treatment in Patients With RAS Mutations in Four Randomised Panitumumab Studies

Clinical Colorectal Cancer
OncologyGastroenterology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy